Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Xdcexplorer (Shanghai) Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, NIEBAUER, RONALD T. The prosecution is occurring within 1 distinct art unit, which indicates a focused examination path for the company's biotechnology assets.
NIEBAUER, RONALD T is the busiest examiner for the portfolio, managing 1 busiest examiner pending action. This single action accounts for the total 1 pending office action currently active. The concentration in a single examiner and art unit suggests a streamlined prosecution effort. For the practitioner, this means that the specific preferences and past decisions of NIEBAUER, RONALD T will be the primary factor in the success of the 1 pending office action within the Biotechnology & Pharmaceuticals sector. By focusing on the requirements of the assigned examiner, the company can tailor its responses to address the specific concerns raised in the pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18593433 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | NIEBAUER, RONALD T | 33d |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18593433 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | NIEBAUER, RONALD T | 1658 | §103 | Final Rejection | 33d | Pending | Mar 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial